Glufosfamide in Treating Patients With Recurrent Glioblastoma Multiforme

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

January 31, 2001

Primary Completion Date

September 30, 2001

Conditions
Brain and Central Nervous System Tumors
Interventions
DRUG

glufosfamide

Trial Locations (18)

1093

Instituto Portugues de Oncologia de Francisco Gentil, Lisbon

21079

Centre de Lute Contre le Cancer,Georges-Francois Leclerc, Dijon

35064

Centre Eugene Marquis, Rennes

35128

Azienda Ospedaliera di Padova, Padova (Padua)

44805

CRLCC Nantes - Atlantique, Nantes-Saint Herblain

49202

Schneider Children's Medical Center of Israel, Petah Tikva

63011

Centre Jean Perrin, Clermont-Ferrand

69373

Centre Leon Berard, Lyon

75651

CHU Pitie-Salpetriere, Paris

A-1100

Kaiser Franz Josef Hospital, Vienna (Wien)

06189

Centre Antoine Lacassagne, Nice

F-94805

Institut Gustave Roussy, Villejuif

GR-45110

University of Ioannina, Ioannina

00161

Istituti Fisioterapici Ospitalieri - Roma, Rome

3075 EA

Rotterdam Cancer Institute, Rotterdam

3508 GA

Academisch Ziekenhuis Utrecht, Utrecht

CH-1011

Centre Hospitalier Universitaire Vaudois, Lausanne

CH-9007

Kantonsspital - St. Gallen, Sankt Gallen

All Listed Sponsors
lead

European Organisation for Research and Treatment of Cancer - EORTC

NETWORK

NCT00014300 - Glufosfamide in Treating Patients With Recurrent Glioblastoma Multiforme | Biotech Hunter | Biotech Hunter